Temozolomide resistance in glioblastoma multiforme

Genes and Diseases

Volumn 3, Issue 3, 2016, Pages 198-210

  Lee, Sang Y ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Adaptive; Glioblastoma; Intrinsic; Resistance; Temodar; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; DRUG MECHANISM; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; NEUROBLASTOMA CELL LINE; NONHUMAN; REVIEW; TREATMENT RESPONSE;

EID: 84983097753     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2016.04.007     Document Type: Review

References (54)

1. 1 Moody, C.L., Wheelhouse, R.T., The medicinal chemistry of imidazotetrazine prodrugs. Pharmaceuticals (Basel) 7 (2014), 797–838.
2. 2 Reid, J.M., Stevens, D.C., Rubin, J., Ames, M.M., Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3 (1997), 2393–2398.
3. 3 Middleton, M.R., Grob, J.J., Aaronson, N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18 (2000), 158–166.
4. 4 Quirt, I., Verma, S., Petrella, T., Bak, K., Charette, M., Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 12 (2007), 1114–1123.
5. 5 Yung, W.K., Prados, M.D., Yaya-Tur, R., et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17 (1999), 2762–2771.
6. 6 Hart, M.G., Garside, R., Rogers, G., Stein, K., Grant, R., Temozolomide for high grade glioma. Cochrane Database Syst Rev, 4, 2013, CD007415.
7. 7 Newlands, E.S., Blackledge, G.R., Slack, J.A., et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65 (1992), 287–291.
8. 8 Cohen, M.H., Johnson, J.R., Pazdur, R., Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 11 (2005), 6767–6771.
9. 9 Alonso, M.M., Gomez-Manzano, C., Bekele, B.N., Yung, W.K., Fueyo, J., Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res 67 (2007), 11499–11504.
10. 10 Baer, J.C., Freeman, A.A., Newlands, E.S., Watson, A.J., Rafferty, J.A., Margison, G.P., Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67 (1993), 1299–1302.
11. 11 Bocangel, D.B., Finkelstein, S., Schold, S.C., Bhakat, K.K., Mitra, S., Kokkinakis, D.M., Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8 (2002), 2725–2734.
12. 12 Kanzawa, T., Bedwell, J., Kondo, Y., Kondo, S., Germano, I.M., Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99 (2003), 1047–1052.
13. 13 Kanzawa, T., Germano, I.M., Kondo, Y., Ito, H., Kyo, S., Kondo, S., Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer 89 (2003), 922–929.
14. 14 Natsume, A., Ishii, D., Wakabayashi, T., et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65 (2005), 7573–7579.
15. 15 Liu, G., Yuan, X., Zeng, Z., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer, 5, 2006, 67.
16. 16 Hermisson, M., Klumpp, A., Wick, W., et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96 (2006), 766–776.
17. 17 Uzzaman, M., Keller, G., Germano, I.M., Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells. J Neurosurg 106 (2007), 646–651.
18. 18 Natsume, A., Wakabayashi, T., Ishii, D., et al. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 61 (2008), 653–659.
19. 19 Ujifuku, K., Mitsutake, N., Takakura, S., et al. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 296 (2010), 241–248.
20. 20 van Nifterik, K.A., van den Berg, J., van der Meide, W.F., et al. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer 103 (2010), 29–35.
21. 21 Goellner, E.M., Grimme, B., Brown, A.R., et al. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res 71 (2011), 2308–2317.
22. 22 Lee, S.Y., Liu, S., Mitchell, R.M., et al. HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A. Int J Cancer 129 (2011), 2104–2114.
23. 23 Agnihotri, S., Gajadhar, A.S., Ternamian, C., et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest 122 (2012), 253–266.
24. 24 Ryu, C.H., Yoon, W.S., Park, K.Y., et al. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol, 2012, 2012, 987495.
25. 25 Happold, C., Roth, P., Wick, W., et al. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem 122 (2012), 444–455.
26. 26 Kohsaka, S., Wang, L., Yachi, K., et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther 11 (2012), 1289–1299.
27. 27 Munoz, J.L., Bliss, S.A., Greco, S.J., et al. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids, 2, 2013, e126.
28. 28 Munoz, J.L., Rodriguez-Cruz, V., Greco, S.J., et al. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis, 5, 2014, e1145.
29. 29 St-Coeur, P.D., Poitras, J.J., Cuperlovic-Culf, M., Touaibia, M., Morin, P. Jr., Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics. J Neurooncol 125 (2015), 91–102.
30. 30 Montaldi, A.P., Godoy, P.R., Sakamoto-Hojo, E.T., APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. Mutat Res Genet Toxicol Environ Mutagen 793 (2015), 19–29.
31. 31 Chong, D.Q., Toh, X.Y., Ho, I.A., et al. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer, 15, 2015, 255.
32. 32 Uno, M., Oba-Shinjo, S.M., Camargo, A.A., et al. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics (Sao Paulo) 66 (2011), 1747–1755.
33. 33 Stupp, R., Mason, W.P., van den Bent, M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005), 987–996.
34. 34 Hegi, M.E., Liu, L., Herman, J.G., et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26 (2008), 4189–4199.
35. 35 Blough, M.D., Beauchamp, D.C., Westgate, M.R., Kelly, J.J., Cairncross, J.G., Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J Neurooncol 102 (2011), 1–7.
36. 36 Wang, Y., Zhu, S., Cloughesy, T.F., Liau, L.M., Mischel, P.S., p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 23 (2004), 1283–1290.
37. 37 Koul, D., Fu, J., Shen, R., et al. Antitumor activity of NVP-BKM120–a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18 (2012), 184–195.
38. 38 Nguyen, S.A., Stechishin, O.D., Lchman, H.A., et al. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute totemozolomide resistance independently of MGMT promoter methylation. Clin Cancer Res 20 (2014), 4894–4903.
39. 39 Ma, J., Murphy, M., O'Dwyer, P.J., Berman, E., Reed, K., Gallo, J.M., Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol 63 (2002), 1219–1228.
40. 40 Bredel, M., Bredel, C., Juric, D., et al. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol 24 (2006), 274–287.
41. 41 Auger, N., Thillet, J., Wanherdrick, K., et al. Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther 5 (2006), 2182–2192.
42. 42 Zhang, J., Stevens, M.F., Laughton, C.A., Madhusudan, S., Bradshaw, T.D., Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 78 (2010), 103–114.
43. 43 Oliva, C.R., Nozell, S.E., Diers, A., et al. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem 285 (2010), 39759–39767.
44. 44 Lee, E.S., Ko, K.K., Joe, Y.A., Kang, S.G., Hong, Y.K., Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. Oncol Lett 2 (2011), 115–121.
45. 45 Ueno, H., Tomiyama, A., Yamaguchi, H., et al. Augmentation of invadopodia formation in temozolomide-resistant or adopted glioma is regulated by c-Jun terminal kinase-paxillin axis. Biochem Biophys Res Commun 468 (2015), 240–247.
46. 46 Wang, X., Jia, L., Jin, X., et al. NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells. Oncol Lett 9 (2015), 2586–2590.
47. 47 McFaline-Figueroa, J.L., Braun, C.J., Stanciu, M., et al. Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide. Cancer Res 75 (2015), 3127–3138.
48. 48 Banelli, B., Carra, E., Barbieri, F., et al. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle 14 (2015), 3418–3429.
49. 49 Giannini, C., Sarkaria, J.N., Saito, A., et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7 (2005), 164–176.
50. 50 Clarke, M.J., Mulligan, E.A., Grogan, P.T., et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 8 (2009), 407–414.
51. 51 Kitange, G.J., Carlson, B.L., Schroeder, M.A., et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11 (2009), 281–291.
52. 52 Hunn, M.K., Bauer, E., Wood, C.E., et al. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. J Neurooncol 121 (2015), 319–329.
53. 53 Quinn, J.A., Jiang, S.X., Reardon, D.A., et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27 (2009), 1262–1267.
54. 54 Dresemann, G., Weller, M., Rosenthal, M.A., et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 96 (2010), 393–402.